Given the importance of EphA5 in resistance to IR treatment, we set out to validate these findings by examining the levels of EphA5 and its effect on response to radiation therapy in an independent cohort of surgically resected tumors from lung cancer patients (n = 23) with stage III non-small cell lung carcinoma, all of whom had undergone radiotherapy following “margin negative” surgery. The gene discussed is EPHA5; the disease is lung cancer.